



## INSILICO STUDY AND DRUG TARGET FOR TYPE II DIABETES FROM A NATURAL COMPOUND

<sup>1</sup>MARTHA LEEEMA ROSE\*, <sup>2</sup>MURUGESH EASWARAN.

<sup>1</sup>Department of Botany, Government Arts College, Salem-636 007, Tamilnadu, India.

<sup>2</sup>Department of Bioinformatics, Bharathiar University, Coimbatore- 641 046.

### ABSTRACT

Diabetes is the most common disease in the world. Especially in India 90 to 95 % people have diabetes. People with type II diabetes tend to have two problems: they don't make quite enough insulin and the cells of their bodies don't seem to take in glucose as eagerly as they should. Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. But still no complete remedy performed to eradicate diabetes on the whole. Our present study focuses on inhibitory concept in cellular level can give drug target for typell (Is it proper to write type '2' uniformly as 'II' as mentioned in title?) diabetes. It was realized that inhibition of all or some of the enzymes like  $\alpha$  - amylase,  $\alpha$  - glucosidase by inhibitors could regulate the absorption of carbohydrate and these inhibitors could be used therapeutically in the oral treatment of the non insulin dependent diabetes mellitus. Mangiferin is a xanthone isolated from roots of *Salacia chinensis* L. is a competitive inhibitor of  $\alpha$  - glucosidase.

**KEY WORDS :** Diabetes,  $\alpha$  - amylase,  $\alpha$  - glucosidase, *Salacia chinensis*.



**MARTHA LEEEMA ROSE**

Department of Botany, Government Arts College,  
Salem-636 007, Tamilnadu, India.

## INTRODUCTION

Diabetes mellitus (DM) often simply referred to as diabetes—is a condition in which a person has high blood sugar, either because the body doesn't produce enough insulin, or because cells don't respond to the insulin that is produced. Here are three main types of diabetes. Type 1 diabetes: results from the body's failure to produce insulin, and presently requires the person to inject insulin. Type 2 diabetes: results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency. Type 3 Gestational diabetes: is when pregnant women, who have never had diabetes before, have a high blood glucose level during pregnancy<sup>1</sup>. It may precede development of type 2 DM. As of 2000 at least 171 million people worldwide suffer from diabetes, or 2.8% of the population. Type 2 DM is by far the most common affecting 90 to 95% of the Indian diabetes population<sup>2</sup>. There are two kinds of medicines: oral medications (pills) and insulin shots. Diabetes pills are not insulin. People with type 2 diabetes tend to have two problems: they don't make quite enough insulin and the cells of their bodies don't seem to take in glucose as eagerly as they should. Anti-diabetic drugs treat DM by lowering glucose levels in the blood<sup>3</sup>. With the exceptions of insulin, exenatide and pramlintide are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors<sup>4</sup>. DM type 2 is a disease of insulin resistance by cells. Treatments include (1) agents which increase the amount of insulin secreted by the pancreas, (2) agents which increase sensitivity of target organs to insulin and (3) agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract<sup>6</sup>. Development of drug concentrate on two ways: target of localization and targets of drugs. By closing the potassium

channels of the pancreatic beta cells, they open the calcium channels, hence enhancing insulin secretion. Since antiquity, diabetes has been treated with plant medicines. Recent scientific investigation has confirmed the efficacy of many reparations, some of which are remarkably effective<sup>5</sup>. Only those herbs that appear the most effective are relatively non-toxic and have substantial documentation of efficacy. Herbal remedies, dietary supplements, and correct life style changes, all together in combination, may reduce or eliminate the need for medication in diabetics<sup>11</sup>. It also helps in preventing some of the tissue and organ damage associated with uncontrolled blood sugar levels. Diabetes has been treated with plant medicines. Those herbs that are most effective are relatively non-toxic<sup>12</sup>. Effective blood glucose control is a key step in the management of type II diabetes to prevent related metabolic complications associated with this disease<sup>7</sup>. Certain plant extracts like *Terminalia chebula* are known to exert insulin like action<sup>3</sup>. In the 1970s it was realized that inhibition of all or some of the enzymes like pancreatic amylase and  $\alpha$  - glucosidase by inhibitors could regulate the absorption of carbohydrate and these inhibitors could be used therapeutically in the oral treatment of the non insulin dependent diabetes mellitus<sup>8</sup>. *Salacia chinensis* L. contains mangiferin a xanthone and a potent competitive  $\alpha$  - glucosidase inhibitor<sup>9</sup>. It is more potent than commercial acarbose. Thus mangiferin provides an alternative to the conventional medical use  $\alpha$  - glucosidase inhibitors<sup>10</sup>.

## METHODS

### Retrieving PDB: (Protein Data Bank)<sup>A</sup>


The X-ray crystallographic structure of the enzyme  $\alpha$  - Amylase(3M07)<sup>B</sup>,  $\alpha$  - Glucosidase(2F2H)<sup>E</sup> was collected from the Protein Data Bank.

### **Finding Active Site of the protein(Receptor)**

What if (Please check the word)server was used to predict the active site of the protein. Total number of active sites of the protein(receptor) 10 based on energy based active site prediction and the residues have been identified<sup>15</sup>.

### **Ligand Preparation**

The set of ligand molecules studied in this work include mangiferin and its structurally similar bioactive compounds. The ligand molecules were retrieved from NCBI-PubChem Compound database<sup>13,H</sup>




**Figure 1**  
**2d Representation of Mangiferin [Pubchem ID CID\_5281647]**

### **Docking Simulation**

In order to carry out the docking simulation, we used the AutoDock 4.0 suite as molecular-docking tool. It is suitable software for performing automated docking


of ligands to their macromolecular receptors. The Graphical User Interface program "AutoDock Tools" was used to prepare, run, and analyze the docking simulation<sup>14</sup>. Results of interaction were viewed using the Molecular visualization software like PyMol.

### **$\alpha$ - Amylase vs Mangiferin**




**Fig 2(a)**  
**Stick representation**


$\alpha$  - Glucidase vs Mangiferin



**Fig 2(b)**  
*Cartoon Representation*



**Fig 3(a)**  
*Stick representation*



**Fig 3(b)**  
*Cartoon Representation*

**Table 1**  
**Interaction Profile**

Receptor Vs Mangiferin	Residues	Atom types		Bond Length	No. H Bonds
		Receptor Ligand			
$\alpha$ - Amylase	ILE 291, ARG	NI, NB	OA, OB4	2.79Å, 3.56 Å,	4
	283, ILE 286, GLY 311	OA, OBA	OBI, OBI	2.60 Å, 3.00 Å,	
$\alpha$ - Glucosidase	ASP 482, ARG	NI, NB,	OA, OB4,	2.46 Å, 3.38 Å,	6
	466, HIS 540,	NAI, NO	OBI, OAI,	3.03 Å, 2.20 Å,	
	ASP 306	OA, OBA	OA2, ODI	3.27 Å, 2.22 Å,	

**Fig 2(a,b):  $\alpha$  – Amylase vs Mangiferin**

- Residues from receptor ILE 291, ARG 283, ILE 286, GLY 311 and its atom types N1, NB - (Nitrogen), OA, OBA - (Oxygen), interacting with Ligand atom types OA, OB4, OB1, OA1 (Oxygen), correspondingly in the Armstrong distance of bond length as 2.79 Å, 3.56 Å, 2.60 Å, 3.00 Å.

**Fig 3(a,b):  $\alpha$  - Glucosidase vs Mangiferin**

Residues from receptor ASP 482, ARG 466, HIS 540, ASP 306 and its atom types N1, NB, NA1, NO - (Nitrogen), OA, OBA - (Oxygen), interacting with Ligand atom types OA, OB4, OB1, OA1, OA2, OD1 (Oxygen), correspondingly in the Armstrong distance of bond length as 2.46 Å, 3.38 Å, 3.03 Å, 2.20 Å, 3.27 Å, 2.22 Å.

## DISCUSSION

In the concise context of above mentioned receptor types that could effectively inhibit Type II diabetes patients from enzymatic process in  $\alpha$  - Glucosidase. Mangiferin inhibits more in cellular level progress. Active site prediction of protein shows ten actively participating residues by its energy based prediction. It varies in all two receptor by its prediction. Each predicted active site has minimum 40 residues and used for docking simulation. In theoretically atom-atom constraint sticks with bound energy format. According to autodock score, energy potential and internal energy system must be low in the interaction profile. As it is mentioned, among two kinds of enzymatic inhibition from mangiferin,  $\alpha$  - glucosidase shows more inhibitory form. Observation of atomic level interaction shows oxygen and nitrogen atoms paves the way to interact with protein and

ligand complex. In the theoretical chemistry, to confirm from bond length we could manage with two atoms and its probable amount of atomic radii. Atomic radii of two atoms forms bond length. Bond length has some limit to manage the energy level in the Autodock procedure. Upper limit and lower limit of the interaction. (Please check the sentence is it heading?) Upper limit considers adding of two atomic radii and lower limit considers minimum possible length to interact. Mangiferin compound has 18 hydrogen atoms, 11 oxygen atoms and 19 carbon atoms. From this atom types from ligand OA, OB4, OB1, OA1, OA2, OD1 occupies the interaction profile with protein (receptor). In the receptor, interaction of atom types contains N1, NB, NA1, NO OA, OBA. All atoms have unique form of identification for programming concept. It is now computationally proved by docking

procedure and its algorithmic form by observing energy value and its number of hydrogen bonds formed between receptor and ligand. It is generally the theoretical consideration of computational hypothesis and applied to our results and observed lower energy value and more number of hydrogen bonds give more stable active compound for

the inhibition of type II Diabetes and accepts the protocol of Lennard Jones Potential(LJ) of receptor and Ligand interaction concept more interacting hydrogen bonds and which have least dockink energy score were considered as good inhibitors. While observing the number of hydrogen bonds.

## CONCLUSION

Bioinformatic study has been carried out to discover insilico drug to combat the serious disorder diabetes. According to bioinformatic mangiferin had 7 hydrogen bonds with the receptor  $\alpha$ - glucosidase. Lower energy value

gives more stable compound for inhibition, focusing from this point mangiferin has least binding energy with  $\alpha$  – glucosidase. Hence  $\alpha$  – glucosidase is considered as the most suitable drug target to treat diabetes.

## ACKNOWLEDGEMENT

I, hereby acknowledge Dr.P.Shanmughavel who really helped to do this computational process in his DBT BIF Lab, Department of Bioinformatics, Bharathiar University, Coimbatore–46

## REFERENCE

1. Awartani F. "Evaluation of the relationship between type 2 diabetes and periodontal disease." *Odontostomatol Trop.* 2009 Dec;32(128):33-9.PMID: 20614697
2. Bordogna A, Pandini A, Bonati L. "Predicting the accuracy of protein-ligand docking on homology models." *J Comput Chem.* 2010 Jul 6. [Epub ahead of print]PMID: 20607693
3. Borgohain R, Lahon K, Das S, Gohain K (Jul 2012). Evaluation of Mechanism of Anti-diabetic activitz of *Terminalia chebula* on Alloxan &Adrenalin induced diabetic Albino rats. *Int J Pharm Bio Sci*, 3<sup>È</sup> 256-266.
4. Choi JH, Choi JN, Lee SY, Lee SJ, Kim K, Kim YK. "Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice." *Arch Pharm Res.* 2010 Feb;33(2):237-42. Epub 2010 Feb 24.PMID: 20195824
5. Cooke DW, Plotnick L (November 2008). "Type 1 diabetes mellitus in pediatrics". *Pediatr Rev* 29 (11): 374–84; quiz 385. doi:10.1542/pir.29-11-374. PMID 18977856.
6. "Diabetes and Aging". *Diabetes Dateline.* National Institute of Diabetes and Digestive and Kidney Diseases. 2002 <http://diabetes.niddk.nih.gov/about/dateline/spr02/8.htm>. Retrieved 2007-05-14.
7. Dong H, Qin S, Zhou HX. "Effects of macromolecular crowding on protein conformational changes." *PLoS Comput Biol.* 2010 Jul 1;6:e1000833.PMID: 20617196
8. Fakhoury WK, Lereun C, Wright D "A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes." *Pharmacology.* 2010 Jul 12;86(1):44-57. [Epub ahead of print]PMID: 20616619 \

9. Lawrence JM, Contreras R, Chen W, Sacks DA (May 2008). "Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999–2005". *Diabetes Care* 31 (5): 899–904. doi:10.2337/dc07-2345. PMID 18223030
10. Liu Q, Chen L, Hu L, Guo Y, Shen X. "Small molecules from natural sources, targeting signaling pathways in diabetes." *Biochem Biophys Acta*. 2010 Jun 23. [Epub ahead of print] PMID: 20601278
11. Matsui T, Ichihara-Tanaka K, Lan C, Muramatsu H, Kondou T, Hirose C, Sakuma S, Muramatsu T. "Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds." *Int Arch Med*. 2010 Jun 21;3:12. PMID: 20565917
12. Nathan DM, Cleary PA, Backlund JY, (December 2005). "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes". *The New England Journal of Medicine* 353 (25): 2643-53. doi:10.1056/NEJMoa052187. PMID16371630.
13. Patlak M (December 2002). "New weapons to combat an ancient disease: treating diabetes". *The FASEB Journal* 16 (14): 1853. PMID 12468446.
14. Paul S. Ciechanowski, M.D.,M.P.H., Wayne J. Katon, M.D., Joan E. Russo, Ph.D., and Edward A. Walker, M.D. "The Patient-Provider Relationship: Attachment Theory and Adherence to Treatment in Diabetes" *Am J Psychiatry* 158:29-35, January 2001
15. Qi LW, Liu EH, Chu C, Peng YB, Cai HX, Li P. "Anti-diabetic agents from natural products--an update from 2004 to 2009." *Curr Top Med Chem*. 2010 Mar;10(4):434-57. PMID: 20180758
16. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H. "Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired fasting Glucose". *Summary of Evidence Report/Technology Assessment, No. 128*. Agency for Healthcare Research and Quality.